
Inari Medical NARI
Quarterly report 2024-Q3
added 10-28-2024
Inari Medical General and Administrative Expenses 2011-2025 | NARI
General and Administrative Expenses — these are a part of a company's operating expenses that are not directly related to the production of goods or the provision of services but are necessary for the overall functioning of the business.What these expenses include
- Salaries of administrative staff (executives, HR, accountants, legal personnel)
- Office rent and utilities
- Office equipment and IT infrastructure
- Professional services (auditors, lawyers, consultants)
- Insurance
- General administrative travel and representation expenses
- Cost control
A high level of such expenses may indicate inefficient management or an overly complex structure - Profitability
Reducing administrative expenses while maintaining stable revenue increases operating profit - Comparative analysis
Investors can compare this metric as a percentage of revenue among companies in the same industry - Business flexibility
Companies with a flexible and controlled expense structure are more resilient to revenue declines
Annual General and Administrative Expenses Inari Medical
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 293 M | 190 M | 89.7 M | 37.2 M | 10.7 M | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 293 M | 10.7 M | 124 M |
Quarterly General and Administrative Expenses Inari Medical
| 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 108 M | 114 M | 103 M | - | 85.6 M | 85.6 M | 85.7 M | - | 75.8 M | 73.2 M | 63.7 M | - | 56.1 M | 42.9 M | 36.9 M | - | 23.1 M | 18.9 M | 16.4 M | - | 10.1 M | 7.8 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 114 M | 7.8 M | 59.2 M |
General and Administrative Expenses of other stocks in the Medical devices industry
| Issuer | General and Administrative Expenses | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
GenMark Diagnostics, Inc.
GNMK
|
25.6 M | - | - | $ 1.77 B | ||
|
Abiomed
ABMD
|
334 M | - | - | $ 17.2 B | ||
|
Acutus Medical
AFIB
|
14.1 M | - | -26.83 % | $ 2.62 M | ||
|
Apyx Medical Corporation
APYX
|
22.2 M | $ 3.86 | -3.26 % | $ 134 M | ||
|
Obalon Therapeutics, Inc.
OBLN
|
8.78 M | - | -5.86 % | $ 30.6 M | ||
|
Bio-Rad Laboratories
BIO
|
814 M | $ 308.13 | - | $ 8.69 B | ||
|
Apollo Endosurgery
APEN
|
20.6 M | - | - | $ 475 M | ||
|
BioSig Technologies
BSGM
|
11.6 M | - | 37.08 % | $ 85.7 M | ||
|
Bruker Corporation
BRKR
|
894 M | $ 45.13 | - | $ 6.72 K | ||
|
Allied Healthcare Products
AHPI
|
7.11 M | - | 3.58 % | $ 2.21 M | ||
|
Abbott Laboratories
ABT
|
11.7 B | $ 125.46 | - | $ 218 B | ||
|
Boston Scientific Corporation
BSX
|
5.98 B | $ 92.58 | - | $ 136 B | ||
|
Conformis
CFMS
|
28.8 M | - | - | $ 16.4 M | ||
|
CryoLife, Inc.
CRY
|
141 M | - | -4.14 % | $ 702 M | ||
|
EDAP TMS S.A.
EDAP
|
5.9 M | $ 2.88 | 22.55 % | $ 107 M | ||
|
Cardiovascular Systems
CSII
|
171 M | - | 0.15 % | $ 844 M | ||
|
Cutera
CUTR
|
63.3 M | - | -10.19 % | $ 1.99 M | ||
|
Soliton, Inc.
SOLY
|
8.46 M | - | -1.42 % | $ 435 M | ||
|
Hancock Jaffe Laboratories, Inc.
HJLI
|
4.88 K | - | -1.98 % | $ 98.3 M | ||
|
Itamar Medical Ltd.
ITMR
|
8.5 M | - | 0.03 % | $ 1.58 B | ||
|
Misonix, Inc.
MSON
|
18 M | - | - | $ 462 M | ||
|
Neovasc
NVCN
|
14.7 M | - | - | $ 111 M | ||
|
Eargo
EAR
|
54.3 M | - | - | $ 10.2 M | ||
|
Dynatronics Corporation
DYNT
|
8.46 M | - | 14.99 % | $ 929 K | ||
|
Intersect ENT, Inc.
XENT
|
98.6 M | - | - | $ 955 M | ||
|
Cognyte Software Ltd.
CGNT
|
163 M | $ 9.86 | - | $ 708 M | ||
|
Second Sight Medical Products
EYES
|
806 K | - | -0.97 % | $ 54.4 M | ||
|
InMode Ltd.
INMD
|
8.41 M | $ 14.51 | - | $ 1.15 B | ||
|
Align Technology
ALGN
|
1.76 B | $ 165.43 | - | $ 12.4 B | ||
|
Accuray Incorporated
ARAY
|
47.9 M | $ 1.06 | -3.64 % | $ 109 M | ||
|
IRIDEX Corporation
IRIX
|
8.75 M | $ 0.92 | -5.12 % | $ 14.8 M | ||
|
IRadimed Corporation
IRMD
|
15.9 M | $ 96.23 | -1.18 % | $ 1.22 B | ||
|
Avinger
AVGR
|
14.1 M | - | -20.74 % | $ 369 K | ||
|
ClearPoint Neuro
CLPT
|
12 M | $ 12.71 | - | $ 344 M | ||
|
FONAR Corporation
FONR
|
23.5 M | $ 14.75 | - | $ 96.7 M | ||
|
AxoGen
AXGN
|
39 M | $ 30.39 | - | $ 1.34 B | ||
|
Axonics Modulation Technologies
AXNX
|
40.2 M | - | - | $ 3.31 B | ||
|
GBS
GBS
|
8.88 M | - | -0.57 % | $ 7.12 M | ||
|
CONMED Corporation
CNMD
|
117 M | $ 40.83 | - | $ 1.26 B | ||
|
OrthoPediatrics Corp.
KIDS
|
103 M | $ 17.6 | -3.98 % | $ 406 M | ||
|
Globus Medical
GMED
|
981 M | $ 86.7 | 0.01 % | $ 11.8 B | ||
|
Integra LifeSciences Holdings Corporation
IART
|
717 M | $ 13.42 | -4.48 % | $ 1.03 B | ||
|
Aziyo Biologics
AZYO
|
14.1 M | - | 1.37 % | $ 20.5 M | ||
|
Alphatec Holdings
ATEC
|
450 M | $ 19.96 | 0.25 % | $ 2.85 B | ||
|
Aethlon Medical
AEMD
|
3.24 M | $ 3.4 | 0.15 % | $ 5.31 M | ||
|
LivaNova PLC
LIVN
|
526 M | $ 62.75 | -1.88 % | $ 3.4 B | ||
|
Establishment Labs Holdings
ESTA
|
140 M | $ 72.51 | - | $ 2.04 B | ||
|
LENSAR
LNSR
|
26.5 M | $ 11.51 | 0.09 % | $ 133 M |